Brief: Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
06/05/2024 13:16
May 6 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ADVANCES TO COHORT 4 OF PHASE 1B
MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE
TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
(ADPKD)
Source text for Eikon: ID:nPnP84tya
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview